This study is looking at an immunotherapy treatment called V940 (mRNA-4157) with pembrolizumab to treat melanoma.

In the randomized, double-blind, phase 3 study, experts explored treatment with neoadjuvant pembrolizumab (Keytruda) plus chemotherapy, followed by adjuvant pembrolizumab, in patients aged 18 years ...

Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was in the spotlight after it rejected a second takeover bid by Cycle Group.

First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended ...

In another positive development for the lung cancer community, NICE has also given its blessing to NHS use of MSD's $25 ...

The imaging agent Gleolan is only approved for glioma surgery, so the current trial could lead to a new indication. In this ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

"Exelixis and MSD to trial cancer therapies together in clinical collaboration" was originally created and published by ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the Phase 3 KEYNOTE-689 trial ...

Researchers have discovered that combining immunotherapy and chemotherapy can overcome treatment resistance in a subset of ...

Alameda, California Tuesday, October 15, 2024, 14:00 Hrs [IST] ...